Clinical trial
Evaluation Of Intraocular Pressure Lowering-Effect Of Xalacom In Patients With…
NCT00143208 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00143208 |
|---|---|
| Title | Evaluation Of Intraocular Pressure Lowering-Effect Of Xalacom In Patients With Poag Or Oh. |
| Official title | Evaluation Of Intraocular Pressure Lowering-Effect Of Xalacom (Fixed Combination Of Latanoprost And Timolol) In Patients With Poag Or Oh. A 6-Month, Open, Multi-Center Trial In Italy |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Glaucoma, Ocular Hypertension |
| Intervention type | Drug |
| Interventions | Xalacom |
| Enrollment | 250 |
| Start date | May 1, 2003 |
| Completion | Apr 1, 2006 |
| First posted | Sep 2, 2005 |
| Last update posted | Feb 21, 2021 |
| Countries | Italy |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: